 The FDA has recently modified the AcelRx Pharmaceuticals Incs NASDAQ: ACRX Dsuvia Risk Evaluation and Mitigation Strategies REMS requirements for healthcare setting audits. The Dsuvia REMS program aims to mitigate the risk of respiratory depression resulting from. 